One-Third of Bermuda Risk Summit Attendees From Overseas
The Bermuda Business Development Agency (BDA) is pleased to announce that its second annual Bermuda Risk Summit, held from March 6-8, attracted 450 attendees, including over 150 business visitors.
The Bermuda Risk Summit creates long-term business development growth potential, in terms of deal-making opportunities occurring around the event in front of an extremely important June 1/July 1 renewal season for Bermuda’s reinsurance sector. The short-term economic impact, including lodging, transportation, food and beverage, retail, and recreation, was estimated at $1.8 million, and supported 266 jobs. This figure includes approximately 100+ additional visitors who flew to Bermuda for business meetings or ancillary events taking place this week around the Bermuda Risk Summit. Our inaugural event, held March 14-16, 2022, attracted 350 delegates, 80 from overseas, had an economic impact $1 million, and supported around 200 jobs.
David Hart, BDA, CEO said, “The BDA thanks all of the companies and leaders from Bermuda’s globally significant Risk and Insurance Solutions industry for their contributions to our event, but more importantly, for their contributions to Bermuda’s economy as a whole. We especially want to thank all of the overseas visitors that made the journey to attend our event. The BDA looks forward to continuing to build and improve upon our annual Risk Summit and welcoming you back in 2024.”
The BDA extends our appreciation to the Association of Bermuda Insurers and Reinsurers (ABIR), EY and Gallagher Re, our headline sponsors; Hyperexponential, our diamond sponsor; SS&C, our gold sponsor; AM Best and Kirkland & Ellis, our silver sponsors; and Aon, Bermuda Brokers, Demotech, Docosoft, Florida Insurance Council, KPMG, Meenan P.A., MS Reinsurance, and Rein4ce our supporting sponsors. The Insurer is our official media partner, and our spirits partner is Goslings.
Bermuda Risk Summit kicked-off with a keynote conversation with Bermuda’s Premier, The Hon. David Burt, JP, MP, followed by a group CEO panel moderated by Sophie Roberts, Head of The Insurer TV, that featured Peter Bell, CEO & Managing Director, Everest Re, Stephen Catlin, Executive Chairman, Convex (Past Chair & Deputy Chair ABIR), Christopher Schaper, CEO, AIG Re (ABIR Deputy Chair), and Megan Thomas, CEO, Hamilton Re. Senior regulators from the Bermuda Monetary Authority, National Association of Insurance Commissioners (NAIC), and the Bank of England’s Prudential Regulatory Authority were also among the speakers.
The BDA is looking forward to its second annual Bermuda Climate Summit, also being held at the Hamilton Princess & Beach Club, from June 26-27, 2023. Sponsorship information is available here – potential attendees can register online.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005685/en/
Contact information
Stuart Roberts, Director of Communications & PR
stuart@bda.bm | +1 441 292 7774
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 09:00:00 EET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i
Azafaros to Present at J.P. Morgan’s 44 th Annual Healthcare Conference8.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 08:00:00 EET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom